Focused On-demand Library for Ubiquitin-conjugating enzyme E2Q-like protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

A1L167

UPID:

U2QL1_HUMAN

Alternative names:

E2Q-like ubiquitin-conjugating enzyme 1

Alternative UPACC:

A1L167

Background:

Ubiquitin-conjugating enzyme E2Q-like protein 1, also known as E2Q-like ubiquitin-conjugating enzyme 1, plays a crucial role in protein ubiquitination, specifically facilitating the monoubiquitination and degradation of key proteins such as MTOR and CCNE1. This process is mediated through its interaction with FBXW7, highlighting its significance in cellular regulation.

Therapeutic significance:

Understanding the role of Ubiquitin-conjugating enzyme E2Q-like protein 1 could open doors to potential therapeutic strategies. Its involvement in the ubiquitination process suggests a pivotal role in cellular homeostasis and disease mechanisms.